Metoprolol Succinate
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension | Adults; pediatrics ≥6 years | Monotherapy or combination | FDA Approved |
| Angina pectoris (chronic stable) | Adults | Monotherapy or combination | FDA Approved |
| Heart failure | Adults (NYHA Class II–IV, stable) | Adjunctive to standard HF therapy | FDA Approved |
Metoprolol succinate is a beta-1 selective (cardioselective) adrenergic receptor blocker formulated for once-daily extended-release dosing. Its selectivity for beta-1 receptors means it primarily affects the heart with less impact on beta-2 receptors in the lungs and vasculature, though selectivity is lost at higher doses. The heart failure indication is based on the landmark MERIT-HF trial, which demonstrated a 34% reduction in all-cause mortality compared with placebo. Unlike metoprolol tartrate (Lopressor), which requires multiple daily doses, the extended-release succinate formulation provides consistent beta-blockade throughout the entire 24-hour dosing interval with lower peak-to-trough fluctuation.
Migraine prophylaxis — AAN Level B recommendation; typical dose 50–200 mg daily (Evidence: Moderate)
Atrial fibrillation / flutter rate control — ACC/AHA/HRS guideline recommended; used for chronic rate control (Evidence: High)
Thyrotoxicosis / thyroid storm — used for heart rate control; beta-blockers are a cornerstone of thyroid storm management (Evidence: Moderate)
Supraventricular tachycardia — used for prophylaxis and rate control in various SVTs (Evidence: Moderate)
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension | 25–100 mg once daily | Titrate to response | 400 mg/day | Titrate at weekly or longer intervals; max effect of given dose seen within 1 week May combine with thiazide diuretics or other antihypertensives |
| Angina pectoris — chronic stable | 100 mg once daily | Titrate to response | 400 mg/day | Increase at weekly intervals until optimal response or pronounced HR slowing Taper over 1–2 weeks if discontinuing; do not stop abruptly |
| Heart failure — NYHA Class II (stable) | 25 mg once daily | Double every 2 weeks | 200 mg/day | Stabilize other HF therapy first; target dose 200 mg/day; do not increase if worsening HF symptoms |
| Heart failure — NYHA Class III–IV (more severe) | 12.5 mg once daily | Double every 2 weeks | 200 mg/day | If transient worsening occurs: increase diuretics, reduce metoprolol dose, or temporarily hold; do not preclude later titration attempts |
| Migraine prophylaxis (off-label) | 25–50 mg once daily | 50–200 mg/day | 200 mg/day | Allow 2–3 months to assess prophylactic efficacy; AAN Level B evidence |
Special Population Dosing
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Pediatric (HTN, ≥6 yrs) | 1 mg/kg once daily (max 50 mg) | Titrate per BP response | 2 mg/kg or 200 mg/day | Primary endpoint not met in pivotal trial; secondary endpoints supported efficacy |
| Hepatic impairment | Lower than recommended | Increase gradually | Individualize | Metoprolol levels substantially increased with hepatic dysfunction; monitor closely for adverse events |
| Renal impairment | Standard dosing | Standard | Standard | No clinically significant change in systemic availability or half-life |
| CYP2D6 poor metabolizers | Consider lower starting dose | Monitor closely | Standard | Metoprolol concentrations approximately doubled; increased risk of bradycardia at standard doses; loss of cardioselectivity at higher concentrations |
Heart failure dosing requires a disciplined, slow up-titration protocol. Start at the lowest dose (12.5 mg for NYHA III–IV, 25 mg for NYHA II) and double the dose every 2 weeks to the target of 200 mg/day or the highest tolerated dose. Stabilize other heart failure medications (ACEi/ARB, diuretics) before initiating metoprolol succinate. If symptomatic bradycardia occurs, reduce the dose. If transient worsening of heart failure occurs, increase diuretics and/or temporarily reduce or hold metoprolol — but initial difficulty with titration should not preclude later re-attempts. The MERIT-HF target dose was 200 mg/day (mean achieved dose 159 mg/day). Abrupt cessation is dangerous and may precipitate myocardial ischemia or infarction.
Metoprolol succinate (Toprol-XL) and metoprolol tartrate (Lopressor) are NOT interchangeable. The succinate salt is formulated as an extended-release tablet for once-daily dosing, while tartrate is an immediate-release product dosed 2–4 times daily. Only metoprolol succinate has the FDA-approved heart failure indication based on MERIT-HF. When switching from tartrate to succinate, the same total daily dose of TOPROL-XL may be used. Tablets are scored and may be halved but must not be crushed or chewed.
Pharmacology
Mechanism of Action
Metoprolol selectively blocks beta-1 adrenergic receptors in cardiac tissue, reducing heart rate, contractility, conduction velocity through the AV node, and renin release. This reduces myocardial oxygen demand (therapeutic in angina), lowers blood pressure (via decreased cardiac output and central sympatholytic effects), and provides neurohormonal modulation in heart failure (attenuating the deleterious chronic activation of the sympathetic nervous system). Beta-1 selectivity is relative and dose-dependent: at higher plasma concentrations, metoprolol also inhibits beta-2 receptors in bronchial and vascular smooth muscle, which explains the potential for bronchospasm at high doses. The extended-release formulation of metoprolol succinate uses multiple controlled-release pellets to deliver metoprolol continuously, producing peak plasma levels approximately one-quarter to one-half those of equivalent conventional metoprolol doses with sustained beta-1 blockade throughout the 24-hour dosing interval.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid and complete absorption; ~50% oral bioavailability (IR) due to first-pass metabolism; ER bioavailability ~77% relative to IR (50–400 mg range); not significantly affected by food; dose-related but not directly proportional increases in bioavailability | Take preferably with or after meals. Non-linear bioavailability means dose adjustments may produce somewhat greater-than-proportional changes in plasma levels. |
| Distribution | Protein binding ~12% (to human serum albumin); racemic mixture (R- and S-enantiomers); lipophilic — crosses blood-brain barrier | Low protein binding minimizes displacement interactions. High lipophilicity explains CNS effects (fatigue, depression, nightmares, insomnia) more than hydrophilic beta-blockers. |
| Metabolism | Extensive hepatic metabolism via CYP2D6 (primary); no clinically active metabolites; CYP2D6 poor metabolizers (~7% of Caucasians): half-life 7–9 h (vs 3–4 h in EM), concentrations approximately doubled | CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine, propafenone) double metoprolol levels, mimicking poor-metabolizer phenotype. Higher concentrations reduce cardioselectivity. Hepatic impairment substantially increases drug levels. |
| Elimination | ~95% recovered in urine; <5% unchanged (EM), up to 30–40% unchanged (PM); t½ 3–4 h (EM), 7–9 h (PM); ER formulation provides continuous release over 24 h; renal failure does not significantly alter systemic availability | No dose adjustment needed for renal impairment. Dialysis does not significantly remove metoprolol. ER formulation compensates for short half-life by continuous controlled release. |
Side Effects
Adverse effect data are from pooled controlled clinical trials of metoprolol (Lopressor PI, all formulations) and the MERIT-HF heart failure trial (Toprol-XL PI, N=1,990 vs N=2,001 placebo). Most adverse effects are mild and transient.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Tiredness / fatigue | ~10% | Most common beta-blocker class effect; related to reduced cardiac output; usually improves over weeks |
| Dizziness | ~10% | Related to blood pressure reduction and heart rate lowering; advise slow position changes; dose-related |
| Depression | ~5% | Lipophilic beta-blockers (metoprolol, propranolol) cross the blood-brain barrier more readily; monitor mood |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Shortness of breath | ~3% | May reflect bronchospasm (especially at higher doses when beta-2 blockade occurs) or worsening HF; evaluate carefully |
| Bradycardia | ~3% (HTN/angina); 1.5% vs 0.4% placebo (MERIT-HF) | Expected pharmacologic effect; dose-related; more common with concurrent AV nodal blockers |
| Diarrhea | >2% | Listed among most common (>2%) adverse reactions in Toprol-XL PI |
| Rash / pruritus | >2% | Listed among most common adverse reactions; can worsen psoriasis in susceptible patients |
| Dizziness / vertigo (MERIT-HF) | 1.8% vs 1.0% placebo | Only AEs exceeding placebo by >0.5% in the MERIT-HF heart failure trial at ≥1% incidence |
| Cold extremities | ~1% | Raynaud-type arterial insufficiency; peripheral vasoconstriction from reduced cardiac output |
| Peripheral edema / hypotension | ~1% | Hypotension more likely during initial titration and with concurrent antihypertensives |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Worsening heart failure | Common during HF titration | During up-titration phase | Increase diuretics; reduce or temporarily hold metoprolol; do not increase dose until stabilized; initial difficulty should not preclude later attempts |
| Severe bradycardia / heart block / cardiac arrest | Rare | Any time; more common with concurrent AV nodal blockers | Reduce or stop metoprolol; atropine, isoproterenol, or pacing as needed; contraindicated in >1st-degree block without pacemaker |
| Bronchospasm | Rare at usual doses; ~1% | Any time; higher risk at high doses or in reactive airway disease | Stop metoprolol; administer beta-2 agonist bronchodilator; use lowest dose if rechallenge necessary |
| Rebound angina / MI (abrupt withdrawal) | Risk with abrupt cessation | Days after abrupt discontinuation | Never stop abruptly; taper over 1–2 weeks; if angina worsens, reinstate promptly |
| Perioperative adverse events (POISE) | Bradycardia 6.6%, hypotension 15%, stroke 1.0%, death 3.1% | Perioperative period | Avoid initiating high-dose ER metoprolol before noncardiac surgery; do not routinely withdraw chronic therapy before surgery |
| Masking of hypoglycemia | Class effect | Any time in diabetic patients or fasting patients | Counsel patients that tachycardia warning sign will be masked; other symptoms (sweating, hunger) remain; monitor blood glucose closely |
Metoprolol is a lipophilic beta-blocker that readily crosses the blood-brain barrier, producing CNS effects at higher rates than hydrophilic beta-blockers (atenolol, nadolol). Tiredness and dizziness affect approximately 10% of patients, and depression occurs in about 5%. Nightmares, insomnia, and short-term memory changes have also been reported. If CNS effects are intolerable, consider switching to a hydrophilic beta-blocker. However, metoprolol’s CNS penetration is part of why it is effective for migraine prophylaxis.
Drug Interactions
Metoprolol is metabolized primarily by CYP2D6. Strong CYP2D6 inhibitors double metoprolol plasma concentrations, increasing both the magnitude of beta-blockade and the risk of losing beta-1 selectivity. Additionally, pharmacodynamic interactions with other drugs that affect cardiac conduction or contractility are clinically important.
Monitoring
- Heart RateEvery visit; each titration
RoutinePrimary pharmacodynamic marker. Target resting HR typically 55–65 bpm for angina/HF. Reduce dose if symptomatic bradycardia or HR consistently <50 bpm. - Blood PressureEach visit; each titration
RoutineMonitor seated and standing. Max antihypertensive effect of a given dose apparent within 1 week. Assess for orthostatic hypotension, especially in elderly and during HF titration. - Heart Failure SymptomsEach titration step (every 2 weeks)
RoutineAssess for worsening dyspnea, weight gain, edema during up-titration. If worsening occurs, increase diuretics and hold or reduce metoprolol dose. Do not increase dose until stabilized. - Blood GlucosePeriodically in diabetic patients
Trigger-basedBeta-blockers mask tachycardia of hypoglycemia but not sweating or hunger. May increase risk of severe or prolonged hypoglycemia. Monitor more closely during fasting or surgery. - Respiratory StatusBaseline and as indicated
Trigger-basedAssess for new wheezing or dyspnea, particularly in patients with reactive airway disease. Beta-1 selectivity is lost at higher concentrations. Have beta-2 agonist available. - Mood / CNS EffectsPeriodically
RoutineDepression (~5%), fatigue (~10%), nightmares, and insomnia are more common with lipophilic beta-blockers. Screen for mood changes, especially in patients with history of depression.
Contraindications & Cautions
Absolute Contraindications
- Severe bradycardia (resting HR significantly below normal)
- Greater than first-degree heart block (second- or third-degree AV block without pacemaker)
- Sick sinus syndrome without a functioning pacemaker
- Cardiogenic shock
- Decompensated heart failure (acute decompensation requiring inotropes or IV diuretics — must be stabilized before initiating)
- Hypersensitivity to metoprolol or any product component
Relative Contraindications (Specialist Input Recommended)
- Bronchospastic disease (asthma, severe COPD) — may use at lowest dose with beta-2 agonist available if no alternative; beta-1 selectivity is not absolute
- Pheochromocytoma — must initiate alpha-blocker first to prevent paradoxical hypertension
- Peripheral vascular disease (severe Raynaud, critical limb ischemia) — may worsen arterial insufficiency
- Moderate to severe hepatic impairment — substantially increased metoprolol levels; start low and monitor
Use with Caution
- Diabetes mellitus — masks tachycardia of hypoglycemia; may prolong or worsen hypoglycemia
- Thyrotoxicosis — abrupt withdrawal may precipitate thyroid storm; taper gradually
- Concurrent CYP2D6 inhibitors — doubled metoprolol levels with loss of cardioselectivity
- Planned noncardiac surgery — avoid initiating high-dose ER metoprolol perioperatively (POISE data: increased stroke and death risk)
- First-degree AV block, WPW, or conduction disorders — increased risk of high-degree block
In a randomized trial of 8,351 patients with or at risk for atherosclerotic disease undergoing noncardiac surgery, initiation of high-dose Toprol-XL (100 mg preoperatively, then 200 mg/day for 30 days) was associated with significantly higher rates of bradycardia (6.6% vs 2.4%), hypotension (15% vs 9.7%), stroke (1.0% vs 0.5%), and death (3.1% vs 2.3%) compared to placebo. Avoid initiating high-dose ER metoprolol in the perioperative setting. However, do not routinely withdraw chronic beta-blocker therapy before surgery, as abrupt cessation carries its own risks.
Patient Counselling
Purpose of Therapy
Metoprolol succinate is prescribed to lower blood pressure, prevent chest pain (angina), or help your heart work more efficiently if you have heart failure. It works by slowing the heart rate and reducing the heart’s workload. For heart failure, the dose is started very low and gradually increased over several weeks.
How to Take
Take once daily, preferably with or immediately after a meal. Swallow the tablet whole or break it in half along the score line — never crush or chew it. Take at the same time each day. If you miss a dose, take only the next scheduled dose; do not double up. Never stop this medication suddenly without talking to your prescriber, as this can cause dangerous rebound effects on the heart.
Sources
- Toprol-XL (metoprolol succinate) Extended-Release Tablets. Full Prescribing Information. Revised March 2023. accessdata.fda.gov Current FDA label for metoprolol succinate ER; source of all approved dosing (HTN, angina, HF), MERIT-HF adverse event data, POISE perioperative data, PK parameters, and CYP2D6 interaction guidance.
- Lopressor (metoprolol tartrate) Tablets and Injection. Full Prescribing Information. Revised 2023. accessdata.fda.gov FDA label for IR metoprolol tartrate; source of adverse effect incidence rates from hypertension/angina trials (tiredness ~10%, dizziness ~10%, depression ~5%, etc.) and MI dosing.
- MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007. doi:10.1016/S0140-6736(99)04440-2 Landmark RCT (N=3,991) demonstrating 34% reduction in all-cause mortality with metoprolol CR/XL vs placebo in chronic HF; the basis for the heart failure indication.
- Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of MERIT-HF. J Am Coll Cardiol. 2002;40(3):491-498. doi:10.1016/S0735-1097(02)01970-8 Dose-response analysis from MERIT-HF confirming that the target dose of 200 mg/day produced maximum benefit; lower doses showed attenuated but still positive effects.
- POISE Study Group, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial). Lancet. 2008;371(9627):1839-1847. doi:10.1016/S0140-6736(08)60601-7 Large RCT (N=8,351) showing that perioperative high-dose metoprolol succinate initiation reduced MI risk but increased stroke and death; basis for the FDA perioperative safety warning.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Current US heart failure guideline; Class I recommendation for beta-blockers (metoprolol succinate, carvedilol, or bisoprolol) in all HFrEF patients who can tolerate them.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for high blood pressure in adults. Hypertension. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065 Current US hypertension guideline; beta-blockers are not first-line for uncomplicated HTN but recommended when a compelling indication exists (HF, post-MI, angina).
- Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78(17):1337-1345. doi:10.1212/WNL.0b013e3182535d20 AAN guideline classifying metoprolol as a Level B (probably effective) agent for episodic migraine prophylaxis.
- Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80(11A):26L-40L. doi:10.1016/S0002-9149(97)00846-1 Seminal review of the neurohormonal rationale for beta-blockade in heart failure, explaining the reversal of adverse cardiac remodeling that underpins MERIT-HF outcomes.
- Dean L, Kane M. Metoprolol therapy and CYP2D6 genotype. In: Medical Genetics Summaries [Internet]. NCBI Bookshelf. 2012; updated 2021. ncbi.nlm.nih.gov NIH pharmacogenomics summary documenting CYP2D6 genotype effects on metoprolol metabolism, clinical implications for poor and ultrarapid metabolizers, and dose adjustment guidance.
- Benfield P, Clissold SP, Brogden RN. Metoprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs. 1986;31(5):376-429. doi:10.2165/00003495-198631050-00002 Comprehensive PK/PD review of metoprolol establishing the pharmacokinetic basis for beta-1 selectivity loss at high plasma concentrations and first-pass metabolism characteristics.
- Morris J, Awosika AO, Dunham A. Metoprolol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Updated February 29, 2024. ncbi.nlm.nih.gov Comprehensive overview of metoprolol pharmacology, dosing across all formulations and indications, adverse effects, CYP2D6 interactions, and clinical monitoring.
- Frishman WH. Carvedilol. N Engl J Med. 1998;339(24):1759-1765. doi:10.1056/NEJM199812103392407 Comparative review of beta-blocker pharmacology placing metoprolol in context with other HF-indicated beta-blockers (carvedilol, bisoprolol), useful for therapeutic selection decisions.